Novartis Ag (NVSEF) Other financing activities (2009 - 2026)

Novartis Ag has disclosed Other financing activities across 16 years of filings, most recently posting $78.0 million for Q1 2026.

• Other financing activities for Q1 2026 came in at $78.0 million, up 239.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$148.0 million (down 223.33% YoY), and the FY2025 annual result was -$203.0 million, down 336.05% from the prior year.
• Other financing activities came in at $78.0 million for Q1 2026 at Novartis Ag, up from -$33.0 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $150.0 million in Q4 2023 to a low of -$215.0 million in Q2 2025.
• The 5-year median for Other financing activities is $23.0 million (2025), against an average of $7.1 million.
• Across the five-year window, Other financing activities sank 2783.33% in 2022 and surged 309.09% in 2025, its largest moves.
• Novartis Ag's Other financing activities stood at -$161.0 million in 2022, then jumped by 193.17% to $150.0 million in 2023, then plunged by 81.33% to $28.0 million in 2024, then plunged by 217.86% to -$33.0 million in 2025, then surged by 336.36% to $78.0 million in 2026.
• The last three Other financing activities figures came in at $78.0 million (Q1 2026), -$33.0 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.